Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
Date:10/22/2010

EXTON, Pa., Oct. 22 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding Cinryze™ (C1 Esterase Inhibitor [Human]) industrial scale manufacturing expansion activities. The FDA has requested additional information related to observations from the pre-approval inspection and review of the technical processes.  

"We and our partner Sanquin will begin working immediately to respond to the FDA as expeditiously as possible," said Vincent Milano, ViroPharma's president and chief executive officer.  "And, we plan to commence manufacturing industrial scale lots at risk in the first quarter of 2011."  

Continued Milano, "We remain committed to provide patients with an uninterrupted supply of Cinryze.  In addition to our efforts around our industrial scale, we expect our currently approved manufacturing process alone will yield up to 60,000 doses annually."

Conference Call and Webcast

ViroPharma is hosting a brief live teleconference and webcast with senior management on October 22, 2010 at 11:00 a.m. Eastern. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com.  Windows Media or Real Player will be needed to access the webcast.  An audio archive will be available at the same address until November 5, 2010.

About Cinryze™ (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 2014 Research and Markets ( ... "Drug Injection Devices to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs become ... of health conditions, drug developers have increasingly pursued ... process and increase the efficiency and reliability with ...
(Date:12/13/2014)... 12, 2014 HudsonAlpha Institute for Biotechnology ... Ten sequencing system manufactured by Illumina, Inc. (NASDQ: ... and analyze genomic data faster and at a ... commitment to research programs for genomics excellence in ... provides unprecedented capacity, speed and accuracy for sequencing ...
(Date:12/13/2014)... and INDIANAPOLIS , Dec. 12, 2014 /PRNewswire/ ... Ganassi Racing Teams (CGRT), today announced a multi-year extension of ... sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing ... IndyCar Series. Kimball, 29, from ... driver with diabetes in the history of INDYCAR to win ...
Breaking Medicine Technology:Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7
...   Sanofi (EURONEXT: SAN and NYSE: ... Scientific American Diabetes Association Sessions,2011, the results of three studies ... and/or,Apidra ® with the insulin delivery device,SoloSTAR ® ... of hypoglycemia vs those,using a premixed insulin product. ...
... June 24, 2011 Advanced BioHealing, Inc. ... technology in the field of regenerative medicine, today announced ... Lewin Group (Falls Church, VA) that showed the addition ... chronic diabetic foot ulcers (DFUs) resulted in a significant ...
Cached Medicine Technology:Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 2Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 3Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 4Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 5Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 6Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 7Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 2Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 3Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 4Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 5
(Date:12/17/2014)... Poor students get more fruits and vegetables at school than ... the opposite is true for students from wealthier families. ... may give a healthy boost to poor students, diets, according ... income level, students all ate a similar amount of fruits ... was published recently in the journal Preventive Medicine . ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... health, but a growing body of evidence shows the ancient ... In fact, the benefits were similar to those of ... Chu, a doctoral candidate at Harvard University,s Health Policy Program ... that people randomly assigned to take yoga classes saw improvements ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Cancer researchers ... possible underlying genetic causes of deadly malignant pleural mesothelioma. ... research on their website. Click here to read ... University of Hawaii Cancer Center, and New York’s Langone ... malignant pleural mesothelioma patients in an effort to ...
(Date:12/15/2014)... Palm Beach, FL (PRWEB) December 15, 2014 ... Care , knows that holidays can be a daze of ... From slips and falls while decking halls, to burns when ... plenty of holiday hazards that can happen at any time. ... for pain, MD Now has made a list of helpful ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Health ... solutions, announced today that it has received Patient ... Assurance (NCQA) for its Disease Management (DM) Programs ... disease (COPD), coronary heart disease and diabetes. This ... NCQA for Health Dialog’s Disease Management (DM) Programs, ...
Breaking Medicine News(10 mins):Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... Real Parental Reassurance, NEW YORK, May 22 ... of biosensor and microprocessor technologies for,use in portable ... for its latest homecare wellness product using SPO,s ... traditional home baby,monitor market., Each year, there ...
... at ... Alma Mater, ... of two fellowships totaling $500,000,in honor of former Chief Executive Officer ... Dr. Garnier, who,received his Masters of Business Administration from the school ...
... SUPPORTS AMERICA,S NEXT GENERATION OF SCIENTISTS, WASHINGTON, ... (the Alliance) announced today the establishment of the,Alliance/Merck ... access to higher education and degrees in science,technology, ... possible,through a $4 million grant from The Merck ...
... Reach of Novel Technology, N. BILLERICA, Mass., ... of cellular bioenergetics, announced today,that Primetech Corporation will ... consumables in Japan., "Japan,s contribution to research ... have seen with the recent acquisition of Millennium ...
... 22 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... leading plasma-based pharmaceutical companies in the,People,s Republic of ... from the Bureau of Health in Guangxi Province ... to a more favorable,location with a wider coverage ...
... projected to climb at double-digit rates, ... according to Millennium Research Group, WALTHAM, Mass., ... for Craniomaxillofacial (CMF) Devices 2008 report,the plate and screw fixation ... nearly $300 million in 2012, driven in part by the ...
Cached Medicine News:Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 2Health News:GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 2Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 4Health News:Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 3Health News:Craniomaxillofacial Plate & Screw Market To Grow to Almost $300 Million by 2012 2
... is a electronic medical records software for ... The Medical Office Records does more than ... designed to follow the flow of your ... previous encounters to establishing new examination records ...
... ChartMaker is a modular, Electronic Medical Record ... Windows to create a patient chart. ChartMaker ... E & M compliant patient notes, medical reports, ... template driven, ChartMaker is designed to be installed ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
Medicine Products: